Pacira BioSciences (PCRX) Cost of Revenue (2010 - 2026)

Pacira BioSciences has reported Cost of Revenue for 17 years, with the latest figure at $44.2 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 8.07% year-over-year to $44.2 million in Q2 2026; TTM through Jun 2026 was $155.2 million, a 0.8% increase from a year earlier, with the FY2025 full-year figure at $149.7 million, down 12.13% from the prior year.
• Cost of Revenue was $44.2 million for Q2 2026 at Pacira BioSciences, up from $36.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $61.9 million in Q4 2022, with the low at $34.3 million in Q3 2025.
• Average Cost of Revenue over 5 years is $43.6 million, with a median of $42.5 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue jumped 58.73% in 2022, then dropped 27.65% in 2025.
• Over 5 years, Cost of Revenue stood at $61.9 million in 2022, then dropped by 22.97% to $47.7 million in 2023, then retreated by 16.37% to $39.9 million in 2024, then grew by 1.04% to $40.3 million in 2025, then climbed by 9.59% to $44.2 million in 2026.
• The last three Cost of Revenue figures came in at $44.2 million (Q2 2026), $36.4 million (Q1 2026), and $40.3 million (Q4 2025), per Business Quant data.